Taylor J E, Henderson I S, Stewart W K, Mactier R A
Department of Medicine, Ninewells Hospital and Medical School, Dundee.
Scott Med J. 1990 Apr;35(2):45-7. doi: 10.1177/003693309003500205.
Calcium carbonate is currently the first choice phosphate binder in renal failure. In the UK its most widely prescribed formulation is a combination of calcium carbonate 420 mg and glycine 180 mg (Titralac 3M Riker). In order to achieve adequate reduction in the serum phosphate level, up to 12 of these tablets may be required daily. In a group of seven patients, we have compared Titralac with two alternative preparations containing calcium carbonate 1250 mg (Calcium-500 Macarthy's Medical Ltd) and calcium carbonate 1260 mg (Calcichew Shire Pharmaceuticals Ltd). Given at a third of the daily number of Titralac tablets, both these newer preparations were effective phosphate binders and produced no statistically significant change in serum calcium and phosphate. The important advantage of such a reduced tablet load is improved patient compliance with phosphate binder therapy. Calcium-500 is also a cost-effective treatment slightly reducing the cost when compared with combined calcium carbonate 420 mg and glycine 180 mg.
碳酸钙目前是肾衰竭患者首选的磷结合剂。在英国，其最常被处方的制剂是碳酸钙420毫克与甘氨酸180毫克的组合（提特拉拉克3M利凯尔公司）。为了使血清磷水平充分降低，每天可能需要多达12片这种药片。在一组7名患者中，我们将提特拉拉克与另外两种含碳酸钙1250毫克的替代制剂（麦卡锡医疗有限公司的钙500）和碳酸钙1260毫克（夏尔制药有限公司的钙奇咀嚼片）进行了比较。给予这些新药片的每日服用量为提特拉拉克药片的三分之一时，这两种新药片都是有效的磷结合剂，且血清钙和磷没有产生统计学上的显著变化。这种减少药片服用量的重要优点是提高了患者对磷结合剂治疗的依从性。与碳酸钙420毫克和甘氨酸180毫克的组合相比，钙500也是一种具有成本效益的治疗方法，略微降低了成本。
